The Impact of Insulin Resistance on Cardiovascular Risk in the Elderly This program has been approved for 1.0 Contact Hour of CPE. Normal certificate processing takes up to two weeks after successful completion of program test.

This program was originally presented as a live audioconference series beginning in July 2002. It was sponsored by the American Society of Consultant Pharmacists, and was accredited for 1.0 hour (0.1 CEUs) under ACPE Universal Program # 203-000-02-493-HO1. If you participated in the live audioconference, you are not eligible to receive continuing pharmaceutical education credit through this online program. This program was supported by an unrestricted grant from GlaxoSmithKline.

Click here to begin the course

Target Audience
This activity has been designed for consultant pharmacists and VA pharmacists.

Learning Objectives On completion of this activity the participant should be able to:
	Discuss the impact of insulin resistance and impaired glucose tolerance on cardiovascular risk in the elderly
	Review the metabolic syndrome and its relationship to cardiovascular disease
	Develop non-pharmacological and pharmacological strategies for the reduction of cardiovascular risk in elderly individuals with diabetes
	Discuss the importance of blood glucose management in reducing cardiovascular risk factors

Program Outline
I.	Case Study
II.	Type 2 Diabetes as a Cardiovascular Risk Factor
III.	Hyperglycemia and Cardiovascular Risk
IV.	The Metabolic Syndrome
V.	Treatment Goals
VI.	Pharmacotherapy and Recommendations
VII.	Case Study I — Wrap Up

Faculty Donald K. Zettervall, RPh, CDE, CDM
	Owner/Director The Diabetes Center Old Saybrook, CT

Don Zettervall has been the owner and director of The Diabetes Center for more than 10 years. In this role he serves as a diabetes disease state manager for more than 40 referring physicians, providing evaluation and recommendations for changes in the patient’s current therapy, exercise prescriptions, meal planning education, initiation and management of insulin and insulin pump therapy, as well as outcome tracking. He currently serves on the Board of Directors and on other active committees for the National Certification Board for Diabetes Educators and is a past board member of the American Association of Diabetes Educators. He also serves as Adjunct Faculty for the University of Connecticut School of Pharmacy.

Disclosure: Mr. Zettervall reports having received honoraria or consulting fees from GlaxoSmithKline, Novo Nordisk, Lifescan and Eli Lilly/Takeda.

This program (#203-000-02-439-HO1) was developed by the American Society of Consultant Pharmacists (ASCP) and is approved for 1.0 Contact Hour (0.1 CEU). ASCP is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. Credit will be awarded upon submission of a completed program evaluation and a post-test with a passing grade of 70% or better. Program Date: July 2002. This program is valid through December 31, 2003.

This program was developed by Medical Communications Media, Inc. and supported by an unrestricted grant from GlaxoSmithKline.

Instructions:

1. The first program screen will permit you to check for or download Flash player which is required to run this program. (1 minute download).
2. Clicking on “start the program” on the next screen will begin the program.
3. Instructions for viewing the program and completing a CE post-test and evaluation will be found on the program’s opening screen. The program will require approximately one hour to complete.
4. A minimum score of 70% on the post-test is required for a CE certificatestatement of credit.